201 related articles for article (PubMed ID: 37777579)
1. DNA damage response inhibitors enhance tumour treating fields (TTFields) potency in glioma stem-like cells.
Vanderlinden A; Jones CG; Myers KN; Rominiyi O; Collis SJ
Br J Cancer; 2023 Nov; 129(11):1829-1840. PubMed ID: 37777579
[TBL] [Abstract][Full Text] [Related]
2. Development and Optimisation of Tumour Treating Fields (TTFields) Delivery within 3D Primary Glioma Stem Cell-like Models of Spatial Heterogeneity.
Jones CG; Vanderlinden A; Rominiyi O; Collis SJ
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473223
[TBL] [Abstract][Full Text] [Related]
3. Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells.
Giladi M; Munster M; Schneiderman RS; Voloshin T; Porat Y; Blat R; Zielinska-Chomej K; Hååg P; Bomzon Z; Kirson ED; Weinberg U; Viktorsson K; Lewensohn R; Palti Y
Radiat Oncol; 2017 Dec; 12(1):206. PubMed ID: 29284495
[TBL] [Abstract][Full Text] [Related]
4. Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy.
Karanam NK; Ding L; Aroumougame A; Story MD
Transl Res; 2020 Mar; 217():33-46. PubMed ID: 31707040
[TBL] [Abstract][Full Text] [Related]
5. Selective Inhibition of Parallel DNA Damage Response Pathways Optimizes Radiosensitization of Glioblastoma Stem-like Cells.
Ahmed SU; Carruthers R; Gilmour L; Yildirim S; Watts C; Chalmers AJ
Cancer Res; 2015 Oct; 75(20):4416-28. PubMed ID: 26282173
[TBL] [Abstract][Full Text] [Related]
6. Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines.
Karanam NK; Srinivasan K; Ding L; Sishc B; Saha D; Story MD
Cell Death Dis; 2017 Mar; 8(3):e2711. PubMed ID: 28358361
[TBL] [Abstract][Full Text] [Related]
7. Biological activity of tumor-treating fields in preclinical glioma models.
Silginer M; Weller M; Stupp R; Roth P
Cell Death Dis; 2017 Apr; 8(4):e2753. PubMed ID: 28425987
[TBL] [Abstract][Full Text] [Related]
8. Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement.
Connelly J; Hormigo A; Mohilie N; Hu J; Chaudhry A; Blondin N
BMC Cancer; 2016 Nov; 16(1):842. PubMed ID: 27809808
[TBL] [Abstract][Full Text] [Related]
9. Tumour treating fields in a combinational therapeutic approach.
Branter J; Basu S; Smith S
Oncotarget; 2018 Nov; 9(93):36631-36644. PubMed ID: 30564303
[TBL] [Abstract][Full Text] [Related]
10. Case report: durable response of gliomatosis cerebri with concurrent tumor-treating fields (TTFields) and chemoradiotherapy treatment.
DesJarlais AM; Miller R; Ali AS; Niazi MZ; Cappelli L; Glass J; Farrell CJ; Shi W
Chin Clin Oncol; 2023 Dec; 12(6):69. PubMed ID: 38195076
[TBL] [Abstract][Full Text] [Related]
11. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.
Clark PA; Gaal JT; Strebe JK; Pasch CA; Deming DA; Kuo JS; Robins HI
J Clin Neurosci; 2017 Feb; 36():120-124. PubMed ID: 27865821
[TBL] [Abstract][Full Text] [Related]
12. An overview of potential novel mechanisms of action underlying Tumor Treating Fields-induced cancer cell death and their clinical implications.
Karanam NK; Story MD
Int J Radiat Biol; 2021; 97(8):1044-1054. PubMed ID: 33086019
[TBL] [Abstract][Full Text] [Related]
13. Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial.
Guberina N; Pöttgen C; Kebir S; Lazaridis L; Scharmberg C; Lübcke W; Niessen M; Guberina M; Scheffler B; Jendrossek V; Jabbarli R; Pierscianek D; Sure U; Schmidt T; Oster C; Hau P; Grosu AL; Stuschke M; Glas M; Nour Y; Lüdemann L
Radiat Oncol; 2020 Apr; 15(1):83. PubMed ID: 32307022
[TBL] [Abstract][Full Text] [Related]
14. Tumor treating fields: a comprehensive overview of the underlying molecular mechanism.
Hong P; Kudulaiti N; Wu S; Nie J; Zhuang D
Expert Rev Mol Diagn; 2022 Jan; 22(1):19-28. PubMed ID: 34883030
[TBL] [Abstract][Full Text] [Related]
15. Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study.
Leal T; Kotecha R; Ramlau R; Zhang L; Milanowski J; Cobo M; Roubec J; Petruzelka L; Havel L; Kalmadi S; Ward J; Andric Z; Berghmans T; Gerber DE; Kloecker G; Panikkar R; Aerts J; Delmonte A; Pless M; Greil R; Rolfo C; Akerley W; Eaton M; Iqbal M; Langer C;
Lancet Oncol; 2023 Sep; 24(9):1002-1017. PubMed ID: 37657460
[TBL] [Abstract][Full Text] [Related]
16. Can tumor treating fields induce DNA damage and reduce cell motility in medulloblastoma cell lines?
Nitta RT; Luo EJ; Lim M; Li G
J Neurosurg Pediatr; 2022 Dec; 30(6):555-566. PubMed ID: 36208441
[TBL] [Abstract][Full Text] [Related]
17. Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models.
Mumblat H; Martinez-Conde A; Braten O; Munster M; Dor-On E; Schneiderman RS; Porat Y; Voloshin T; Davidi S; Blatt R; Shteingauz A; Tempel-Brami C; Zeevi E; Lajterer C; Shmueli Y; Danilov S; Haber A; Giladi M; Weinberg U; Kinzel A; Palti Y
Lung Cancer; 2021 Oct; 160():99-110. PubMed ID: 34482104
[TBL] [Abstract][Full Text] [Related]
18. Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.
Fishman H; Monin R; Dor-On E; Kinzel A; Haber A; Giladi M; Weinberg U; Palti Y
J Neurooncol; 2023 May; 163(1):83-94. PubMed ID: 37131108
[TBL] [Abstract][Full Text] [Related]
19. DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies.
Rominiyi O; Collis SJ
Mol Oncol; 2022 Jan; 16(1):11-41. PubMed ID: 34036721
[TBL] [Abstract][Full Text] [Related]
20. AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields).
Shteingauz A; Porat Y; Voloshin T; Schneiderman RS; Munster M; Zeevi E; Kaynan N; Gotlib K; Giladi M; Kirson ED; Weinberg U; Kinzel A; Palti Y
Cell Death Dis; 2018 Oct; 9(11):1074. PubMed ID: 30341282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]